FGFR1 and metastatic neoplasm: Because of the relatively small number of cases with FGFR1 amplification in this study, it is not possible to determine whether the survival of this patient group is significantly different to the group of “poor responders” as a whole, and whether FGFR1 amplification in osteosarcoma contributes to the risk of metastatic disease.